Healthcare
No matter how we manage our health, efficacy, risks and costing are top concernsProstate cancer treatment with 5-AR drugs may increase the cancer progress
As the trial of antiandrogenic drugs of Dutasteride and Finasteride; a 5-alpha reductase (5-AR) inhibitor drug to treat enlargement of prostate size or benign prostatic hyperplasia (BPH) including hair loss caused by androgenic alopecia, showed mixture in result, the U.S Food and Drug Administration (FDA) just release a caution to healthcare professionals to be aware of increase prostate cancer progress, although the rate risk might be not so high.
Therefore, when prescribed of drugs classified as 5-AR, the physicians should have best estimation whether the benefits outweigh the risk.
The trials, Prostate Cancer Prevention Trial (PCPT) for Finasteride and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) for Dutasteride were purposed whether these drugs have potential chemopreventive properties.
Overall, although the results showed reduction in prostate cancer progress for the Gleason score (GS, a prostate cancer criteria based on microscopic appearance) of 6 or lower, but there also increase the prostate cancer progress for GS of prostate cancer of 8 to 10.
Related Posts:
Subscribe for latest health news via email
